Incannex Healthcare Inc

The company maintains a strong liquidity position, with a current ratio of 5.7 and $9.3 million in cash and equivalents, which is significantly higher than the typical liquidity requirements for a firm in its industry. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce its financial flexibility.

Profitability metrics are negative, with a return on equity of -42.66% and a return on assets of -34.96%, indicating that the company is not generating returns for shareholders or effectively utilizing its assets. These figures are well below the industry median for return on equity and return on assets, which are typically positive for firms in the biotechnology and medical research sector.

Geographically, the company's revenue is concentrated in a limited number of markets, with no detailed breakdown provided in the available data. However, the lack of diversification could expose the company to regional regulatory or market risks. The company's product portfolio is also limited, with no clear indication of multiple revenue streams or diversification across therapeutic areas.

The company's growth trajectory is uncertain, with no clear revenue growth in the most recent fiscal year and negative operating and net income. Analysts have estimated a mean EPS of -$1.85 for the upcoming period, which is an improvement from the last actual EPS of -$40.50, but still indicates a lack of profitability. The absence of capital expenditures and the company's focus on cash preservation suggest a conservative approach to growth.

Risk factors include the company's negative net income and operating cash flow, which could impact its ability to fund operations without external financing. The low dilution risk is attributed to the absence of immediate filing-based flags, but the company's reliance on cash reserves and the absence of long-term debt could change if market conditions deteriorate. The governance ESG score of 7.26 indicates potential governance concerns, which could affect stakeholder confidence.

Recent events include the filing of financial statements that show continued losses and a lack of revenue growth. The company has not issued new shares recently, and there are no indications of upcoming equity offerings or significant changes in its capital structure. The controversies ESG score of 100.00 suggests that the company has not been involved in any major ESG-related controversies, which is a positive signal for investors.

The company maintains a zero long-term debt balance across all reported fiscal periods, indicating a conservative capital structure.

Incannex Healthcare exhibits a current ratio of 2.86, suggesting strong short-term liquidity to meet immediate obligations.

Revenue surged 616.7% year-over-year to $86,000 in the latest period, marking a significant operational milestone.

The firm ranks best-in-class for cash conversion within its biotechnology cohort, outperforming the median significantly.

Operating losses narrowed by 15.9% year-over-year, demonstrating improved cost management despite continued net income deficits.

The company reported a net loss of $46.9 million in the latest fiscal year, highlighting persistent unprofitability.

Operating income +19,1% YoY; Net income +34,2% YoY.

• ▍Operating income +19,1% YoY
• ▍Net income +34,2% YoY
• ▍Free cash flow +34,1% YoY

Revenue $12.0k; Operating income -$5.0M.

• ▍Revenue $12.0k
• ▍Operating income -$5.0M
• ▍Net margin -49116.7%

Revenue $74.0k; Operating income -$6.3M.

• ▍Revenue $74.0k
• ▍Operating income -$6.3M
• ▍Net margin -7324.3%